Revolution Medicines drug daraxonrasib nearly doubles survival in advanced pancreatic cancer trial.
An experimental pill called daraxonrasib helped patients with advanced pancreatic cancer live longer in a clinical trial of 500 patients. Those taking the drug had a median survival of 13.2 months compared with 6.7 months for chemotherapy recipients. The results were presented Sunday at the American Society for Clinical Oncology meeting in Chicago and published in the New England Journal of Medicine.
3
Divergence score
8 outlets covered it, splitting into 8 framing camps across 4 bias groups.
8 camps
4 bias groups
Market signalBETA
The spectrum · how 8 outlets placed this story
LeftCenterRight
Washington Times
Reuters
Newsmax
CNN
Le Monde
PBS NewsHour
NY Post
Deutsche Welle
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Coverage now splits three ways: clinical breakthrough framed as hope or 'grand slam,' realistic limitations emphasizing it's not a cure, and prevention/strategy context, with PBS and DW tempering optimism while NY Post sensationalizes via celebrity case.
How each outlet covered it
Broad agreement on what happened
Outlets across the spectrum land in roughly the same place: the shared language is highlighted.
3LOW DIVERGENCE
THE RIGHT
“Experimental Pill Promises New Hope for Deadly Pancreatic Cancer - Newsmax”NM Newsmax RIGHT
DOWN THE MIDDLE
“Pancreatic cancers: New drug doubles survival rate as France rolls out prevention program” · Reuters, Le Monde, PBS NewsHour, Deutsche Welle
+Hide the full sourcingSee how all 8 outlets put it
CENTER2
RReuters Revolution's pancreatic cancer drug doubles survival, boosts quality of life 50d ago PBSPBS NewsHour Experimental drug shows promise against deadly pancreatic cancer 50d ago 6 tracked claims across 8 outlets
Fact ledger
All6Claimed1Corroborated5
1/8
Claimed
The drug is developed by Revolution Medicines.
Corroborated
Disputed
5 more tracked claimsSign up free to see the full ledger